Global Development
Executing high-quality clinical trials
In Global Development we develop new proteins and peptides from early phases to market penetration. We aim to ensure a global leadership position within diabetes, haemostasis and growth hormone treatment as well as building presence in inflammation.
Based on our high quality and ethical standards, we strive to achieve optimal product profiles and lifecycles to maximise the value of our portfolio, and we have a proven track-record of maximising labels globally.
Our clinical development expertise is solid. It is based on extensive experience with large, global, complex, multi-centre clinical trials for therapies targeting both large and niche market segments. US Investigative Sites rated Novo Nordisk the top sponsor in 2007 ahead of 19 other pharmaceutical companies, according to the Thomson CenterWatch Monthly, May 2007.
We dare say that within diabetes, in particular, our clinical trial designs are world class. The same goes for patient recruitment and trial execution - and within diabetes we are the fastest in the world, according to the Centre for Medicines Research.
Our global reach
We work in global project teams, using all competencies in the organisation with a clear focus on delivering viable products that clearly benefit society - fast.
Clinical trials are conducted out of Clinical Development Centres in North America, Europe, Japan and China.
To ensure best practice, skills and knowledge in development of therapies, we work with the world’s leading academic centres and preferred industrial partners.
See our other units in R&D
Diabetes Research Unit
Biopharmaceutical Research Unit
Regulatory Affairs
CMC Supply
